Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,644.95
(
0.46%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 177248

Thursday, 04/24/2014 1:47:47 PM

Thursday, April 24, 2014 1:47:47 PM

Post# of 257302

GILD—Credit Suisse: likely price of all-oral at $100K for 8 week regimen…

Does CS say what they’re modeling for the 12-week regimen? $150K?

As previously posted (#msg-100491031), I think the US list price of the 8-week Sovaldi + Ledipasvir regimen will be ~$67K and the list price of the 12-week regimen will be ~$100K—i.e. linear pricing. dewophile (#msg-100469795) and jq1234 (#msg-100849128) have identical or nearly identical forecasts.

What are your own forecasts for these prices?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today